The Health Resources and Services Administration issued a stern warning to Johnson & Johnson on Sept. 17, stating the company’s plans to impose 340B rebates on certain drugs are in violation of federal law.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
